Kamada

Kamada’s sterile manufacturing facility is used to produce plasma derived pharmaceutical therapies.

Kamada Plasma, a 2021 subsidiary, specializes in collecting rare donors’ plasma for KamRho-D, a life-saving medicine manufactured and distributed by Kamada.

Kamada’s growth stems from its employees’ vision, skills, and dedication, including becoming the first Israeli company to gain FDA approval for a biological drug.

Amir London became Kamada’s CEO in July 2015 after serving as Senior Vice President of Business Development. He brings over 20 years of senior management and international business experience.

Kamada partners with industry collaborators to combine strengths and create a greater whole. Its strategic collaborations include an exclusive agreement with Takeda for manufacturing, marketing, and distributing Glassia in the United States and Canada.

The purpose of the Code of Ethics is to put into force within the organization written and binding moral principles and values as a guide for specific behavioral rules that are compulsory for the managers and employees of the company at every level, and to act according to them.

Kamada, established over three decades ago, develops and distributes specialty-plasma therapies through its U.S. subsidiary, Kamada Inc.

Kamada is a vertically integrated biopharmaceutical company focused on plasma-derived therapeutics, with marketed products, a development pipeline, and industry-leading manufacturing.

Kamada introduces two new biosimilar products in Israel, expanding its portfolio in the region. The company targets annual revenue of around $10 million from its biosimilars, commercialized in Israel and the MENA region. This growth follows the launch of additional products in its expanding biosimilars lineup.

Oct 2026GlobeNewswireNews article

The U.S. Centers for Disease Control and Prevention (CDC) reports a sharp rise in nationwide rabies exposures and the use of anti-rabies immunoglobulin. Kamada Ltd. confirms its KedRAB® supply is adequate to address the heightened demand driven by these exposures. The company’s product is a key treatment for rabies prevention in exposed individuals.

Sep 2026GlobeNewswireNews article

Kamada declares a $0.17-per-share cash dividend while reporting record-high revenue and profitability for the first six months of 2026. The company aligns the dividend with its established cash dividend policy. Financial results highlight sustained growth in earnings and operational efficiency.

Aug 2026GlobeNewswireNews article

Kamada achieves record first-half 2026 revenues of **$100.2 million**, a **13% year-over-year increase**, alongside a **$25.7 million adjusted EBITDA**—its highest margin at **26%**—marking double-digit profitable growth. The company’s financial performance surpasses prior records, reinforcing its strongest results in history. Kamada also reaffirms its **2026 annual guidance** amid sustained profitability and operational strength.

Aug 2026GlobeNewswireNews article